PH12021552018A1 - Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate - Google Patents

Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Info

Publication number
PH12021552018A1
PH12021552018A1 PH1/2021/552018A PH12021552018A PH12021552018A1 PH 12021552018 A1 PH12021552018 A1 PH 12021552018A1 PH 12021552018 A PH12021552018 A PH 12021552018A PH 12021552018 A1 PH12021552018 A1 PH 12021552018A1
Authority
PH
Philippines
Prior art keywords
trifluoromethyl
crystalline form
dihydroisoquinolin
pyrazole
pyridin
Prior art date
Application number
PH1/2021/552018A
Other languages
English (en)
Inventor
Robert Michael Geertman
Kristof Leonard Kimpe
Carina Leys
Haojuan Wei
Peng Zhou
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12021552018A1 publication Critical patent/PH12021552018A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2021/552018A 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate PH12021552018A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (1)

Publication Number Publication Date
PH12021552018A1 true PH12021552018A1 (en) 2022-09-19

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552018A PH12021552018A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Country Status (21)

Country Link
US (1) US12269813B2 (enExample)
EP (1) EP3927696B1 (enExample)
JP (1) JP2022523368A (enExample)
KR (1) KR20210131371A (enExample)
CN (1) CN113474339B (enExample)
AU (1) AU2020226723B2 (enExample)
BR (1) BR112021016400A2 (enExample)
CA (1) CA3129623A1 (enExample)
EA (1) EA202192320A1 (enExample)
EC (1) ECSP21067828A (enExample)
ES (1) ES2966132T3 (enExample)
IL (1) IL285675A (enExample)
JO (1) JOP20210227A1 (enExample)
MA (1) MA55019A (enExample)
MX (1) MX2021010133A (enExample)
PE (1) PE20212067A1 (enExample)
PH (1) PH12021552018A1 (enExample)
SG (1) SG11202108909SA (enExample)
TW (1) TW202045495A (enExample)
UY (1) UY38592A (enExample)
WO (1) WO2020169736A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
BR112023003106A2 (pt) 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022326183A1 (en) * 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525183A (ja) 2003-04-30 2007-09-06 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN102947270B (zh) 2010-06-22 2015-04-08 巴斯夫欧洲公司 制备4-羟基吡啶的方法
MX2014014531A (es) * 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
HUE044351T2 (hu) 2014-05-28 2019-10-28 Novartis Ag Új pirazolo-pirimidin származékok és azok alkalmazása MALT1 inhibitorként
EP3177366A4 (en) 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
CA3003820A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
US11571427B2 (en) 2017-12-28 2023-02-07 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
WO2019161921A1 (de) 2018-02-23 2019-08-29 Industrieanlagen-Betriebsgesellschaft Mbh Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
BR112023003106A2 (pt) * 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo

Also Published As

Publication number Publication date
CN113474339A (zh) 2021-10-01
US20220127249A1 (en) 2022-04-28
CA3129623A1 (en) 2020-08-27
EP3927696A1 (en) 2021-12-29
JOP20210227A1 (ar) 2023-01-30
IL285675A (en) 2021-10-31
WO2020169736A1 (en) 2020-08-27
TW202045495A (zh) 2020-12-16
ECSP21067828A (es) 2021-11-18
AU2020226723B2 (en) 2025-01-23
UY38592A (es) 2020-08-31
JP2022523368A (ja) 2022-04-22
CN113474339B (zh) 2025-02-25
SG11202108909SA (en) 2021-09-29
AU2020226723A1 (en) 2021-08-19
PE20212067A1 (es) 2021-10-26
ES2966132T3 (es) 2024-04-18
MX2021010133A (es) 2021-09-23
EP3927696B1 (en) 2023-10-18
EA202192320A1 (ru) 2021-11-16
MA55019A (fr) 2021-12-29
US12269813B2 (en) 2025-04-08
KR20210131371A (ko) 2021-11-02
BR112021016400A2 (pt) 2021-10-13
EP3927696C0 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
PH12021552018A1 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
PH12020551304A1 (en) Novel crystalline forms
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
NZ627464A (en) Fungicidal pyrazole mixtures
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
MX343837B (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
MY183536A (en) Pharmaceutical compositions comprising azd9291
MX2017006447A (es) Agentes antifungicos.
NZ719975A (en) Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound
NZ604035A (en) Glycine transporter-1 inhibitors, methods of making them, and uses thereof
PL3464276T3 (pl) Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
PH12021553202A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
BR112021023074A2 (pt) Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida
PH12020500040A1 (en) Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
MX2025003559A (es) Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtencion
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MX386586B (es) Cristal de base libre de derivados benzofurano y método de preparación.
CR20210605A (es) N-(prid-3-il)carboxamidas fungicidas
EA201892687A1 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
HK40065506A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
MX2017016042A (es) Polimorfos de un compuesto de triazol que inhibe la pges-1.
MX2022006134A (es) Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida.
PH12021553191A1 (en) Stable polymorphic form of 6-fluoro-9-methyl-9h-ãŸ-carboline and uses thereof
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19